Yes, a PICC line can infiltrate, though not the way a peripheral IV does. Because the tip sits in the superior vena cava, infiltration almost always signals a different failure. The catheter fractured, the tip drifted backward into a smaller vein, or the line was never truly central. Reported rates run about 1% to 6% in adults and 5% to 8% in neonatal units. Peripheral IVs infiltrate in roughly 10% to 30% of adults and 20% to 70% of children. The signs differ as well, which is why central infiltrations get missed.
Can PICC Lines Infiltrate When the Tip Is Central?
A peripheral IV sits in a vein 2 to 4 mm across, held by a short catheter and a strip of tape. Fluid escapes easily. A correctly placed PICC tip sits in the superior vena cava, a vessel roughly 20 mm wide in adults. Flow there runs 2.0 to 2.5 liters per minute. At ordinary infusion pressures of 2 to 15 psi, the vessel accepts fluid faster than any pump delivers it. In plain terms: a genuinely central tip has room and flow on its side, which is why the SVC rarely leaks at the tip itself.
So infiltration through a PICC requires a second problem on top of the catheter. Four failure routes account for most reported events, and each produces a different clinical picture.
The first is a break in catheter integrity. Fractures, pinholes, and failed repair sites leak fluid into the soft tissue of the arm or chest wall, not at the tip. Reported fracture rates run 1.5% to 3% over a catheter's life, climbing after roughly 12 months of dwell. These leaks announce themselves at the hub or along the visible tract, which makes them the easiest PICC infiltrations to catch.
The second is tip migration. A PICC tip that backs out of the SVC can land in the brachiocephalic vein, the internal jugular, the azygos vein, or the internal thoracic vein. Published migration rates fall between 3% and 12% over dwell. The azygos is the most dangerous destination, because infusing total parenteral nutrition or a vesicant into a 4 to 6 mm mediastinal vein can produce a mediastinal extravasation with no arm swelling at all.
The third route is a line that was never central to begin with. Between 10% and 25% of bedside-placed PICCs sit short of the cavoatrial junction at the time of the confirmatory image, especially with left-sided insertions. Arm position changes between the radiograph and the first infusion shift the tip by 1 to 3 cm in either direction.
The fourth is vessel wall erosion, and it is the rarest. Catheter-related perforation of the SVC occurs in roughly 0.2% to 1% of central catheters, typically weeks to months after placement. Left-sided catheters, corticosteroid exposure, and a tip abutting the vessel wall at a sharp angle are the commonly cited risk factors. Whether steroids act independently or simply mark a sicker population remains unsettled. These cases present late, with a new pleural effusion or mediastinal widening after an infusion.
How Often PICC Lines Infiltrate, by Patient Group
The vocabulary has to be fixed before the numbers mean anything. Per the Infusion Nurses Society standards, infiltration is leakage of a non-vesicant solution into surrounding tissue, while extravasation is leakage of a vesicant. The physical event is identical. The consequences are not: a vesicant binds DNA in local cells and can produce full-thickness necrosis from a few milliliters.
With that settled, adult inpatient PICCs show infiltration or extravasation in about 1% to 6% of catheters. Neonatal intensive care runs higher, at 5% to 8%, and infants under 1,000 g sit at the top of that band because their vessel walls are thinner and their catheters are proportionally larger. Oncology series tracking vesicants through central devices report extravasation in 0.1% to 4.9%, with contemporary single-center figures clustering near 0.5%.
Those ranges overlap heavily, and the overlap is the story. Series that count radiographically confirmed contrast leakage find several times more events than series that count only visible tissue injury. Where one report cites 0.5% and another cites 6%, the gap is usually definition and detection method, not biology. The device class sets the baseline risk; tip position and catheter integrity decide everything above it.
| Device | Tip location | Typical dwell | Reported infiltration or extravasation | Vesicant use |
|---|---|---|---|---|
| Peripheral IV | Forearm or hand vein | 3 to 4 days | 10% to 30% adult; 20% to 70% pediatric | Short pushes only |
| Midline | Axillary or basilic vein, below the axilla | 1 to 4 weeks | 3% to 10% | Avoided for continuous vesicants in most policies |
| PICC | Cavoatrial junction | Weeks to 12 months | 1% to 6% adult; 5% to 8% neonatal | Yes |
| Tunneled CVC or port | Cavoatrial junction, tunneled | Months to years | Under 1% | Yes |
Time Course of a PICC Infiltration Injury
Fewer than 20 mL of a non-vesicant can produce visible swelling in a forearm. In the mediastinum, several times that volume can accumulate before anything shows on the skin. Vesicant injury, by contrast, follows a predictable clock regardless of volume, which is what makes recognition speed the single most modifiable variable.
| Time after the leak | What is happening | What to look for |
|---|---|---|
| 0 to 2 hours | Fluid accumulates in the interstitial space; 10 to 50 mL is often needed before swelling is visible | Vague fullness, mild discomfort, no pump alarm |
| 2 to 6 hours | Edema becomes visible; inflammatory mediators enter the tissue | Taut skin, pain out of proportion, blanching |
| 6 to 24 hours | Vesicant binds local DNA and proteins; erythema and blistering begin | Sharp demarcation line, blisters, cool skin |
| 24 to 72 hours | Necrosis demarcates and ulceration deepens | Darkening tissue, early eschar, pain sometimes easing |
| 3 to 14 days | Eschar matures; surgical service assesses for debridement | Full-thickness loss, contracture risk over a joint |
| 2 to 8 weeks | Healing by secondary intention, or grafting | Scarring, stiffness, loss of range of motion |
The 6-hour mark in that table is not decorative. For anthracycline extravasation, dexrazoxane given within 6 hours of the leak reduces the need for surgical debridement substantially, a finding established in the landmark trial by Mouridsen and colleagues in 2007. After 24 to 72 hours, the injury is largely determined, and management shifts from pharmacology to wound care.
Signs and Red Flags
The classic teaching is swelling at the IV site, and with a PICC that teaching fails outright. The leak may be in the chest while the arm looks perfectly normal. Both presentations belong on the same checklist, and any one of the following stops the infusion.
- New swelling of the arm, shoulder, neck, or chest on the catheter side, especially when one side is measurably larger.
- Pain or burning during the infusion that persists after the pump stops.
- A visible bulge or fluid leak at the hub, the repair site, or anywhere along the subcutaneous tract.
- Absent blood return combined with resistance to a gentle 10 mL flush.
- Skin changes over the tract: blanching, tautness, coolness, or a sharp line of demarcation.
- After a chest-position leak: new dyspnea, pleural effusion, or mediastinal widening on imaging.
Two of those deserve commentary. Absent blood return is a weak test. It appears in a large share of properly functioning PICCs and disappears intermittently with position, so its presence proves little in either direction. And many infusion pumps will not alarm during an infiltration, because soft tissue accepts fluid at low pressure; most devices only flag an occlusion once line pressure reaches roughly 5 to 15 psi, and an arm can absorb fluid well below that threshold.
Five Misconceptions About PICC Infiltration
The first misconception is that central means safe. Central describes the tip location at the moment of confirmation, not at hour 600 of a 90-day dwell. Arm circumference, hub position, and blood return all need rechecking, because the tip does not stay where the radiograph found it.
The second is that only peripheral IVs infiltrate. PICC lines can infiltrate, and the central position makes the event harder to spot rather than less likely to happen.
The third is that a PICC and a midline are the same device. A midline terminates in the axillary or basilic vein, well below the shoulder, and infiltrates at 3% to 10%, several times the PICC rate. A meaningful share of published "PICC infiltrations" are midlines or short-tipped catheters mislabeled at insertion. In plain terms: the label on the chart is not the anatomy in the arm.
The fourth is that blood return proves the line is intravascular. It does not, and flushing to confirm patency during a suspected vesicant extravasation pushes more drug into tissue.
The fifth is that pinch-off syndrome happens with PICCs. Pinch-off is a subclavian catheter phenomenon, caused by compression between the clavicle and the first rib. PICCs enter below the clavicle and bypass that space entirely. When a PICC fractures, the cause is usually hub damage, a stressed repair site, or connector torque, not bony compression. That distinction changes where you look for the leak.
What to Actually Do When a PICC Infiltrates
Stop the infusion the moment suspicion arises. Disconnect the tubing, but leave the catheter in place. Removal is a decision for the clinician managing the extravasation, not an automatic reflex.
Do not flush to test patency. For a vesicant, every milliliter pushed is additional drug delivered into tissue. Aspirate gently instead, using a 10 mL syringe, to withdraw residual drug from the lumen. Syringe size matters more than most clinicians expect: a 3 mL syringe generates roughly three times the pressure of a 10 mL syringe at the same hand force, which can turn a small leak into a large one.
For vesicants, call pharmacy and oncology before removing the device. Central catheters are often kept for 24 to 48 hours so an antidote plan can be executed. Anthracycline extravasation gets dexrazoxane, and the clock starts at the moment of leakage, not at the moment of diagnosis.
Apply the correct compress. Cold packs are standard for anthracyclines, taxanes, and most vesicants. Vinca alkaloids, meaning vincristine and vinblastine, are the notable exception and take warm compresses instead, because cooling worsens their local toxicity.
Then measure, photograph, and document. Record the drug, concentration, estimated volume, time of onset, and limb circumference at a fixed landmark on both arms. Elevate the affected limb above heart level for 24 to 48 hours and recheck circumference every 8 to 12 hours. Restart therapy through a different site, ideally the opposite arm.
Prevention deserves as much space as rescue. Confirm blood return before every vesicant dose, use 10 mL or larger syringes for flushing, and secure the catheter with a sutureless device rather than tape alone. Measure baseline arm circumference at insertion and repeat it each shift. Avoid blood pressure cuffs and venipuncture on the catheter arm. Re-image the tip after any episode of severe vomiting or coughing, or after the hub appears to have retracted 2 cm or more. And if a CT contrast bolus is planned, verify the catheter is labeled for power injection, typically rated to 300 psi at 5 mL per second; a standard PICC exposed to that pressure can fail at the hub.
Limits of the Evidence
No randomized trial has assigned patients to different PICC infiltration strategies, and none is likely. Most incidence figures come from single-center retrospective cohorts of 50 to 300 catheters, with inconsistent definitions and inconsistent imaging confirmation.
Neonatal registries are the weakest link, because some bundle PICCs with peripheral catheters when reporting extravasation. Long-term outcomes such as scarring, joint contracture, and limb function are rarely tracked beyond three months. Ultrasound guidance and tip-confirmation technology have lowered malposition rates at insertion, but neither device follows the tip through a 12-month dwell. The risk window stays open long after the insertion note is signed.